Entero Therapeutics Inc.
ENTO
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.58M
Close$
$0.01
99.8% downside
Current Fair Value
99.8% downsideOvervalued by 99.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $13.58 Million |
|---|---|
| Enterprise Value | $15.69 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.16 |
| Beta | 1.19 |
| Outstanding Shares | 4,451,298 |
Return
| Return on Equity | -37.00% |
|---|---|
| Return on Assets | -18.21% |
| Return on Invested Capital | -31.12% |
Valuation & Multiples
| P/E Ratio | -2.86 |
|---|---|
| PEG | -1.65 |
| Price to Sales | - |
| Price to Book Ratio | 0.48 |
| Enterprise Value to Revenue | 210.69 |
| Enterprise Value to EBIT | -1.59 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Entero Therapeutics Inc.
12 employees
CEO: James Sapirstein azurrx biopharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. ms1819 recombinant lipase for exocrine pancreatic insufficiency is ...